Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease

被引:16
作者
Yan, Zhonghong [1 ]
Wang, Guanran [1 ,2 ]
Shi, Xingyang [1 ]
机构
[1] Heilongjiang Univ Chinese Med, Harbin, Peoples R China
[2] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Dept Nephrol, Tianjin, Peoples R China
关键词
biomarkers for early diagnosis; progression biomarkers; prognostic biomarkers; chronic kidney disease; advances; GROWTH-FACTOR; 23; TRIMETHYLAMINE-N-OXIDE; TO-MESENCHYMAL TRANSITION; CORONARY-ARTERY-DISEASE; BONE TURNOVER MARKERS; P-CRESYL SULFATE; DIABETIC-NEPHROPATHY; MATRIX METALLOPROTEINASES; DIFFERENTIATION FACTOR-15; PARATHYROID-HORMONE;
D O I
10.3389/fphar.2021.785375
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic kidney disease (CKD) is one of the increasingly serious public health concerns worldwide; the global burden of CKD is increasingly due to high morbidity and mortality. At present, there are three key problems in the clinical treatment and management of CKD. First, the current diagnostic indicators, such as proteinuria and serum creatinine, are greatly interfered by the physiological conditions of patients, and the changes in the indicator level are not synchronized with renal damage. Second, the established diagnosis of suspected CKD still depends on biopsy, which is not suitable for contraindication patients, is also traumatic, and is not sensitive to early progression. Finally, the prognosis of CKD is affected by many factors; hence, it is ineviatble to develop effective biomarkers to predict CKD prognosis and improve the prognosis through early intervention. Accurate progression monitoring and prognosis improvement of CKD are extremely significant for improving the clinical treatment and management of CKD and reducing the social burden. Therefore, biomarkers reported in recent years, which could play important roles in accurate progression monitoring and prognosis improvement of CKD, were concluded and highlighted in this review article that aims to provide a reference for both the construction of CKD precision therapy system and the pharmaceutical research and development.
引用
收藏
页数:20
相关论文
共 245 条
  • [1] Expression of miRNAs-122,-192 and-499 in end stage renal disease associated with acute myocardial infarction
    Abdelsalam, Lobna
    Ibrahim, Alshaymaa A.
    Shalaby, Aliaa
    Osman, Noha
    Hashad, Assem
    Badawy, Dina
    Elghobary, Hany
    Amer, Eman
    [J]. ARCHIVES OF MEDICAL SCIENCE, 2019, 15 (05) : 1247 - 1253
  • [2] Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure
    Aimo, Alberto
    Vergaro, Giuseppe
    Ripoli, Andrea
    Bayes-Genis, Antoni
    Figal, Domingo A. Pascual
    de Boer, Rudolf A.
    Lassus, Johan
    Mebazaa, Alexandre
    Gayat, Etienne
    Breidthardt, Tobias
    Sabti, Zaid
    Mueller, Christian
    Brunner-La Rocca, Hans-Peter
    Tang, W. H. Wilson
    Grodin, Justin L.
    Zhang, Yuhui
    Bettencourt, Paulo
    Maisel, Alan S.
    Passino, Claudio
    Januzzi, James L.
    Emdin, Michele
    [J]. JACC-HEART FAILURE, 2017, 5 (04) : 287 - 296
  • [3] Update on Inflammation in Chronic Kidney Disease
    Akchurin, Oleh M.
    Kaskel, Frederick
    [J]. BLOOD PURIFICATION, 2015, 39 (1-3) : 84 - 92
  • [4] Expression of microRNA-377 and microRNA-192 and their potential as blood-based biomarkers for early detection of type 2 diabetic nephropathy
    Al-Kafaji, Ghada
    Al-Muhtaresh, Haifa Abdulla
    [J]. MOLECULAR MEDICINE REPORTS, 2018, 18 (01) : 1171 - 1180
  • [5] Inflammation and Progression of CKD: The CRIC Study
    Amdur, Richard L.
    Feldman, Harold I.
    Gupta, Jayanta
    Yang, Wei
    Kanetsky, Peter
    Shlipak, Michael
    Rahman, Mahboob
    Lash, James P.
    Townsend, Raymond R.
    Ojo, Akinlolu
    Roy-Chaudhury, Akshay
    Go, Alan S.
    Joffe, Marshall
    He, Jiang
    Balakrishnan, Vaidyanathapuram S.
    Kimmel, Paul L.
    Kusek, John W.
    Raj, Dominic S.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 11 (09): : 1546 - 1556
  • [6] Physical Activity in Relation to Serum Sclerostin, Insulin-Like Growth Factor-1, and Bone Turnover Markers in Healthy Premenopausal Women: A Cross-Sectional and a Longitudinal Study
    Ardawi, Mohammed-Salleh M.
    Rouzi, Abdulrahim A.
    Qari, Mohammed H.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (10) : 3691 - 3699
  • [7] Cardiac Biomarkers and Risk of Incident Heart Failure in Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study
    Bansal, Nisha
    Zelnick, Leila
    Go, Alan
    Anderson, Amanda
    Christenson, Robert
    Deo, Rajat
    Defilippi, Christopher
    Lash, James
    He, Jiang
    Ky, Bonnie
    Seliger, Stephen
    Soliman, Elsayed
    Shlipak, Michael
    Appel, Lawrence J.
    Feldman, Harold, I
    Go, Alan S.
    Lash, James P.
    Rao, Panduranga S.
    Rahman, Mahboob
    Townsend, Raymond R.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (21):
  • [8] Gut-Microbiota-Metabolite Axis in Early Renal Function Decline
    Barrios, Clara
    Beaumont, Michelle
    Pallister, Tess
    Villar, Judith
    Goodrich, Julia K.
    Clark, Andrew
    Pascual, Julio
    Ley, Ruth E.
    Spector, Tim D.
    Bell, Jordana T.
    Menni, Cristina
    [J]. PLOS ONE, 2015, 10 (08):
  • [9] Head- to- Head Comparison of 2 Myocardial Fibrosis Biomarkers for Long-Term Heart Failure Risk Stratification
    Bayes-Genis, Antoni
    de Antonio, Marta
    Vila, Joan
    Penafiel, Judith
    Galan, Amparo
    Barallat, Jaume
    Zamora, Elisabet
    Urrutia, Agustin
    Lupon, Josep
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (02) : 158 - 166
  • [10] Soluble ST2 Serum Concentration and Renal Function in Heart Failure
    Bayes-Genis, Antoni
    Zamora, Elisabet
    De Antonio, Marta
    Galan, Amparo
    Vila, Joan
    Urrutia, Agustin
    Diez, Crisanto
    Coll, Ramon
    Altimir, Salvador
    Lupon, Losep
    [J]. JOURNAL OF CARDIAC FAILURE, 2013, 19 (11) : 768 - 775